PolarityTE IncNASDAQ:PTENASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8093
- TODAY'S CHANGE (%)-0.0007 (-0.0864%)
- Bid / Lots0.7902/ 1
- Ask / Lots0.8250/ 1
- Open / Previous Close0.8100 / 0.8100
- Day Range
- 52 Week Range
- Volume22,057
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PTE |
|---|---|---|
| 09:32 ET | 106 | 0.81 |
| 09:35 ET | 2501 | 0.8021 |
| 09:37 ET | 992 | 0.80605 |
| 09:42 ET | 100 | 0.802 |
| 09:46 ET | 1400 | 0.806049 |
| 09:48 ET | 1000 | 0.806049 |
| 10:08 ET | 127 | 0.806051 |
| 10:33 ET | 2804 | 0.8022 |
| 10:44 ET | 100 | 0.8022 |
| 10:45 ET | 1000 | 0.8022 |
| 10:47 ET | 2932 | 0.7903 |
| 11:59 ET | 680 | 0.8073 |
| 12:08 ET | 100 | 0.805 |
| 12:21 ET | 100 | 0.8001 |
| 12:24 ET | 1196 | 0.7923 |
| 12:26 ET | 350 | 0.8 |
| 12:28 ET | 1358 | 0.7903 |
| 12:51 ET | 200 | 0.799 |
| 01:18 ET | 1500 | 0.8056 |
| 01:27 ET | 900 | 0.81 |
| 01:31 ET | 100 | 0.809899 |
| 02:05 ET | 243 | 0.790101 |
| 02:16 ET | 100 | 0.8 |
| 03:39 ET | 100 | 0.809299 |
| 03:53 ET | 200 | 0.8093 |
| 03:57 ET | 207 | 0.8093 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PolarityTE Inc | 5.9M | -0.2x | --- |
NovaBay Pharmaceuticals Inc | 4.6M | -0.4x | --- |
Petros Pharmaceuticals Inc | 5.8M | -1.9x | --- |
Rosetta Genomics Ltd | 590.0 | 0.0x | --- |
Epigenomics AG | 6.5M | 0.0x | --- |
PhaseBio Pharmaceuticals Inc | 737.9K | 0.0x | --- |
Company Information
PolarityTE, Inc. is a biotechnology company. The Company is focused on developing regenerative tissue products and biomaterials. It also operates a laboratory testing and clinical research business using equipment, personnel, and facilities it acquired to advance its development of regenerative tissue products. Its first regenerative tissue product is SkinTE, which is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The Company's development projects include SkinTE Cryo, SkinTE point-of-care device, PTE 11000, and others.
Contact Information
- Headquarters
- 1960 S. 4250 WestSALT LAKE CITY, UT, United States 84104
- Phone
- 385-266-3151
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Peter Cohen
- President, Chief Executive Officer
- Richard Hague
- Interim Chief Financial Officer
- Jacob Patterson
- Executive Vice President - Corporate Development & Strategy, General Counsel
- Cameron Hoyler
- Director
- Jeff Dyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9M |
|---|---|
Revenue (TTM) | $1.9M |
Shares Outstanding | 7.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-4.22 |
Book Value | $5.83 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,640.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
